Tepha Inc subsidiary Galatea Surgical said today it won FDA 510(k) clearance for its GalaForm 3D surgical scaffold device designed for use in plastic and reconstructive surgery. The Lexington, Mass.-based company claims that the GalaForm 3D scaffold is the only 3-dimensionally contoured surgical scaffold with a reinforcing rim designed to uplift the body’s shape for […]
Implantable medical device developer Tepha said today it completed a buy-out of its roylaty obligations with former licensor and parent company Metabolix. Get the rest of the story at our sister site, Medical Design & Outsourcing
Absorbable biomaterial developer Metabolix said it amended its license agreement with medical device company Tepha, forgoing future royalties and providing 2 additional Metabolix production strains and related IP in exchange for a $2 million lump sum. Read the full story at our sister site, Medical Design & Outsourcing.
Tepha Inc. stitched up nearly $3 million in new funding from a group of un-named investors, according to a filing with the federal Securities and Exchange Commission.
The Lexington, Mass.-based company, a 1998 spinout from Cambridge, Mass.-based Metabolix (NSDQ:MBLX), is developing absorbable polymers for surgical sutures, mesh, implants and cardiovascular devices.